Drugs / CLF065
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07226050 | Jun 2026 → Mar 2027 | pouchitis | Calibr, a division of Scripps Research | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLF065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226050 ↗ |
| Modality | Peptide | “CLF065 is a long acting Glucagon-like peptide-2 (GLP-2).” NCT07226050 ↗ |
| Route | Subcutaneous | “CLF065 or a placebo as a subcutaneous injection (just under the skin) once a week” NCT07226050 ↗ |